29 February 2024 in JACCP: Journal of the American College of Clinical Pharmacy
1 May 2023 in JACCP: Journal of the American College of Clinical Pharmacy
Simulation, an educational, assessment, and research technique used to mimic real‐world situations, is increasingly used in pharmacy education. The most‐used simulation methods include high‐fidelity simulation (HFS), low‐fidelity simulation (LFS), standardized patients, and game‐based simulation. A common element of simulation is its ability to offer learners the chance to practice a skill or acquire knowledge in a safe and accessible space. Simulation methods differ in key aspects, including cost and other resource investment as well as ideal venue for use in education. HFS provides a more realistic simulation environment than LFS but is typically more expensive. Standardized patients offer learners the opportunity to engage with a live person but may elicit greater variability in responses to learners' input than HFS. Computer‐based simulation uses technology to supply a wide variety of learning opportunities; however, it may require the use of proprietary software and devices. Despite widespread use, literature describing learning outcomes of simulation in pharmacy education is limited. Some existing reports with positive findings have focused on learner satisfaction with or perceived benefit of simulation activities. The few existing publications summarizing changes in skills or knowledge demonstrate a positive impact. Simulation is a promising modality for educating pharmacy students and residents; however, more data summarizing the benefit of learning outcomes are needed.
3 April 2014 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
25 November 2022 in Journal of Pharmacy Practice
Complications throughout the peripartum period may be caused by preexisting conditions or pregnancy-induced conditions and may alter pharmacotherapy management. Pharmacotherapy management during late pregnancy and delivery requires careful consideration due to changing hormones, hemodynamic status, and pharmacokinetics, and concerns for potential maternal and/or fetal morbidity. Increased maternal and fetal monitoring are often required and may lead to therapy changes. Pharmacists, as key members of the interprofessional team, can contribute essential perspective to the management of postpartum pharmacotherapy through assessment and recommendation of appropriate and judicious use of medications.
27 April 2025 in Journal of the American Pharmacists Association
Transgender and gender-diverse (TGD) people may self-administer injectable estradiol or testosterone therapy for gender-affirming hormone therapy (GAHT). Knowledge about injection-related safety and injection adherence for TGD people remains to be determined. To determine the types of injection-related safety issues and medication adherence issues reported in the literature for TGD people on injectable GAHT. Our secondary objective was to identify opportunities for pharmacists to enhance the self-injection experience for TGD people on injectable GAHT. We examined the literature to determine the types of issues TGD people experience when prescribed injectable GAHT. We searched for English language publications in PubMed and Google Scholar from inception to 5 August 2024 (e.g., "transgender," "nonbinary," "self-inject*," "estrogens," "testosterone") and included original research publications that assessed one of three injection-related domains: Safety (injection site-related reactions or pain, psychological safety around injections), injection-related medication administration (individual self-injection practices and preferences including family or caregiver support administering injections, access to appropriate injection supplies, continuation of injections, patient-reported comfort) and teaching and assessment of injection practices by a pharmacist or other health care provider (clinic- or pharmacy-based injection counseling or follow-up assessments). We excluded articles that did not describe whether GAHT was self-injected and publications about long-acting injectable testosterone undecanoate, as trained providers administer this medication. Seven publications discussed at least one of the three injection-related domains. Investigators used various methods for assessing these elements across publications. Although self-injected GAHT was well-tolerated overall, most publications reported injection site reactions that were managed while continuing self-injected GAHT. Gaps included comprehensive teaching and assessment of individual self-injection practices long-term. Based on the types of injection-related challenges identified, pharmacists, as one of the most accessible health care providers in the United States, are well-positioned to intervene and improve the experience of patients using injectable GAHT.
12 August 2025 in JACCP: Journal of the American College of Clinical Pharmacy